Evidence map›Paper›PMID 22473918›Full record

SynthesisArthritis care & research2012

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Jaclyn Anderson, Liron Caplan, Jinoos Yazdany, Mark L Robbins, Tuhina Neogi, Kaleb Michaud, Kenneth G Saag, James R O'Dell, Salahuddin Kazi

4 registry-linked trialsAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Arthritis care & research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 347 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
347citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02556034 completednot on this mapstarted 2015, after this paper: background citation

Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)

TypeobservationalSponsorIsabelle FortinRan2015 to 2018Enrolled80ConditionsRheumatoid Arthritis, Psoriatic ArthritisArmsDisease evaluation.
NCT03656627 phase1terminatednot on this mapstarted 2019, after this paper: background citation

Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

TypeinterventionalSponsorAlliance Foundation Trials, LLC.Ran2019 to 2021Enrolled7ConditionsAutoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, PsoriasisArmsNivolumab
NCT05291299 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Anti-Inflammatory Dietary Intervention for Rheumatoid Arthritis

TypeinterventionalSponsorAttune Health Research, Inc.Ran2022 to 2025Enrolled32ConditionsRheumatoid ArthritisArmsAnti-inflammatory diet, Control/Standard of Care
NCT05627089 withdrawnnot on this mapstarted 2023, after this paper: background citation

Rheumatoid Arthritis and Myositis Cohort

TypeobservationalSponsorAttune Health Research, Inc.Ran2023 to 2035Enrolled0ConditionsRheumatoid Arthritis, Myositis
3 · Its place in the literature

Who cites it

347 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Effect ofNutrients · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

287 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jaclyn AndersonUniversity of Nebraska Medical Center, Omaha, NE, USA.
Liron Caplan
Jinoos Yazdany
Mark L Robbins
Tuhina Neogi
Kaleb Michaud
Kenneth G Saag
James R O'Dell
Salahuddin Kazi

Funding

Evaluating Health Care Quality in Systemic Lupus ErythematosusK23AR060259 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YAZDANY, JINOOS · 2011 to 2015
$638k
NIAMS NIH HHS K23 AR060259
6 · The paper itself

Abstract

objectiveAlthough the systematic measurement of disease activity facilitates clinical decision making in rheumatoid arthritis (RA), no recommendations currently exist on which measures should be applied in clinical practice in the US. The American College of Rheumatology (ACR) convened a Working Group (WG) to comprehensively evaluate the validity, feasibility, and acceptability of available RA disease activity measures and derive recommendations for their use in clinical practice.

methodsThe Rheumatoid Arthritis Clinical Disease Activity Measures Working Group conducted a systematic review of the literature to identify RA disease activity measures. Using exclusion criteria, input from an Expert Advisory Panel (EAP), and psychometric analysis, a list of potential measures was created. A survey was administered to rheumatologists soliciting input. The WG used these survey results in conjunction with the psychometric analyses to derive final recommendations.

resultsSystematic review of the literature resulted in identification of 63 RA disease activity measures. Application of exclusion criteria and ratings by the EAP narrowed the list to 14 measures for further evaluation. Practicing rheumatologists rated 9 of these 14 measures as most useful and feasible. From these 9 measures, the WG selected 6 with the best psychometric properties for inclusion in the final set of ACR-recommended RA disease activity measures.

conclusionWe recommend the Clinical Disease Activity Index, Disease Activity Score with 28-joint counts (erythrocyte sedimentation rate or C-reactive protein), Patient Activity Scale (PAS), PAS-II, Routine Assessment of Patient Index Data with 3 measures, and Simplified Disease Activity Index because they are accurate reflections of disease activity; are sensitive to change; discriminate well between low, moderate, and high disease activity states; have remission criteria; and are feasible to perform in clinical settings.

Indexed as

Severity of Illness IndexAntirheumatic AgentsArthritis, RheumatoidHealth SurveysHumansPractice Guidelines as TopicRheumatologySocieties, MedicalUnited StatesAntirheumatic Agents

Identifiers

PMID22473918
PMCPMC4028066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.